RS58448B1 - Antitela protiv antigena matičnih ćelija specifičan za prostatu i njihova upotreba - Google Patents

Antitela protiv antigena matičnih ćelija specifičan za prostatu i njihova upotreba

Info

Publication number
RS58448B1
RS58448B1 RS20190218A RSP20190218A RS58448B1 RS 58448 B1 RS58448 B1 RS 58448B1 RS 20190218 A RS20190218 A RS 20190218A RS P20190218 A RSP20190218 A RS P20190218A RS 58448 B1 RS58448 B1 RS 58448B1
Authority
RS
Serbia
Prior art keywords
antibody
psca
seq
antibodies
cells
Prior art date
Application number
RS20190218A
Other languages
English (en)
Serbian (sr)
Inventor
Michael Bachmann
Original Assignee
Gemoab Monoclonals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemoab Monoclonals Gmbh filed Critical Gemoab Monoclonals Gmbh
Publication of RS58448B1 publication Critical patent/RS58448B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RS20190218A 2011-06-30 2012-06-29 Antitela protiv antigena matičnih ćelija specifičan za prostatu i njihova upotreba RS58448B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
EP12729996.4A EP2726507B1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
PCT/EP2012/062716 WO2013001065A1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung

Publications (1)

Publication Number Publication Date
RS58448B1 true RS58448B1 (sr) 2019-04-30

Family

ID=46384405

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190218A RS58448B1 (sr) 2011-06-30 2012-06-29 Antitela protiv antigena matičnih ćelija specifičan za prostatu i njihova upotreba

Country Status (18)

Country Link
US (1) US9200078B2 (OSRAM)
EP (2) EP3505536B1 (OSRAM)
JP (4) JP2014528696A (OSRAM)
AU (1) AU2012277784B2 (OSRAM)
CY (1) CY1121249T1 (OSRAM)
DE (1) DE102011118022B4 (OSRAM)
DK (1) DK2726507T3 (OSRAM)
ES (2) ES2989975T3 (OSRAM)
HR (1) HRP20190289T1 (OSRAM)
HU (1) HUE042008T2 (OSRAM)
LT (1) LT2726507T (OSRAM)
PL (1) PL2726507T3 (OSRAM)
PT (1) PT2726507T (OSRAM)
RS (1) RS58448B1 (OSRAM)
SI (1) SI2726507T1 (OSRAM)
SM (1) SMT201900085T1 (OSRAM)
TR (1) TR201901991T4 (OSRAM)
WO (1) WO2013001065A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
AU2021276327A1 (en) * 2020-05-19 2022-12-01 City Of Hope Engineered anti-prostate stem cell antigen fusion proteins and uses thereof
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
WO2024233662A2 (en) * 2023-05-09 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to psca polypeptides
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
WO1998040403A1 (en) * 1997-03-10 1998-09-17 The Regents Of The University Of California Psca: prostate stem cell antigen
DK1226177T3 (da) * 1999-10-29 2008-10-06 Genentech Inc Antistofsammensætninger mod anti-prostata stamcelle-antigen (PSCA) og anvendelser deraf
KR101229731B1 (ko) * 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 cd3-바인더
JP4651663B2 (ja) * 2004-05-28 2011-03-16 アジェンシス,インコーポレイテッド Pscaタンパク質に結合する抗体および関連分子
CA2698343C (en) * 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
BRPI0919840B1 (pt) * 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Also Published As

Publication number Publication date
PL2726507T3 (pl) 2019-06-28
ES2711978T3 (es) 2019-05-08
JP6886491B2 (ja) 2021-06-16
LT2726507T (lt) 2019-04-10
US20140134155A1 (en) 2014-05-15
JP2021121201A (ja) 2021-08-26
AU2012277784B2 (en) 2015-08-20
SI2726507T1 (sl) 2019-05-31
EP2726507B1 (de) 2018-11-21
DE102011118022B4 (de) 2018-01-18
HRP20190289T1 (hr) 2019-05-03
JP2014528696A (ja) 2014-10-30
EP3505536A1 (de) 2019-07-03
ES2989975T3 (es) 2024-11-28
DE102011118022A1 (de) 2013-01-03
DK2726507T3 (en) 2019-03-11
WO2013001065A1 (de) 2013-01-03
US9200078B2 (en) 2015-12-01
JP7341185B2 (ja) 2023-09-08
JP6549622B2 (ja) 2019-07-24
PT2726507T (pt) 2019-02-26
HUE042008T2 (hu) 2019-06-28
EP3505536B1 (de) 2024-08-07
AU2012277784A1 (en) 2014-02-06
TR201901991T4 (tr) 2019-03-21
CY1121249T1 (el) 2020-05-29
EP2726507A1 (de) 2014-05-07
EP3505536C0 (de) 2024-08-07
JP2019193652A (ja) 2019-11-07
JP2017104113A (ja) 2017-06-15
SMT201900085T1 (it) 2019-05-10

Similar Documents

Publication Publication Date Title
JP7341185B2 (ja) 前立腺特異幹細胞抗原に対する抗体およびその使用
CN109476735B (zh) Flt3和cd3的抗体构建体
AU2010299895B2 (en) Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses
US11414497B2 (en) Anti-PSMA antibodies and use thereof
US12421292B2 (en) Anti-DLL3 chimeric antigen receptors and uses thereof
TW202023611A (zh) 針對cldn18.2和cd3之抗體構建體
US9540446B2 (en) Anti-La antibodies and their use for immunotargeting
US9249217B2 (en) Bispecific EGFRvIII x CD3 antibody engaging molecules
US10053514B2 (en) Human bispecific EGFRvIII and CD3 antibody engaging molecules
CA2876133C (en) Human bispecific egfrviii antibody engaging molecules
KR20230104229A (ko) Cd3에 결합하는 폴리펩티드 구축물
JP2024513700A (ja) 抗ワクシニアウイルス抗原抗体並びに関連する組成物及び方法
CN114213536B (zh) Cd133抗体、嵌合抗原受体及其应用
CN114316050B (zh) Cd133抗体、嵌合抗原受体及其应用
HK1197419A (en) Antibodies against prostate-specific stem cell antigen and use thereof
HK1197419B (en) Antibodies against prostate-specific stem cell antigen and use thereof
CN114478767A (zh) 特异性结合cd33的嵌合抗原受体及其应用